Resolute ZES (zotarolimus-eluting stent) / Medtronic - LARVOL DELTA

"Roundabout" Bailout Stenting for Subacute Right Coronary Artery Obstruction After Self-Expandable Transcatheter Aortic Valve Replacement. (PubMed, JACC Case Rep) - "A "roundabout" approach via the adjacent cusp may allow coronary access and revascularization when the coronary sinus is sequestered."

Journal • Cardiovascular

FAME 3: A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease (clinicaltrials.gov) - P=N/A | N=1500 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Coronary Artery Disease

Postpartum Spontaneous Coronary Artery Dissection Involving the Left Main Coronary Artery: A Case Report. (PubMed, Int J Womens Health) - "A 3.0 ×22-mm Endeavor Resolute stent was implanted in the proximal LM and left anterior descending coronary arteries...However, after withdrawal of the IABP and VA-ECMO, the patient's symptoms worsened, and she died while awaiting heart transplantation. We report a rare case of PSCAD involving the LM coronary artery with the aim of enhancing clinicians' understanding of PSCAD and providing insights for treatment approaches."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Myocardial Infarction • Pain • Transplantation

Submaximal Stenting' for Rescue Therapy in Large Vessel Occlusion (LVO) Acute Ischemic Stroke Secondary to Intracranial Atherosclerotic Disease (ICAD): A Single-Center Case Series (ISC 2026) - "All patients underwent follow-up vascular imaging. Complications are illustrated based on duration since admission in Figure 2 .Conclusions Submaximal stenting with Resolute Onyx™ and Onyx Frontier™ DES is technically feasible and appears safe as rescue therapy for acute IS related to ICAD-LVO."

Clinical • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials. (PubMed, Ann Med) - "For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD."

Clinical • HEOR • Journal • Retrospective data • Review • Cardiovascular • Myocardial Infarction

A prospective, multicenter, randomized controlled study to evaluate the safety and efficacy of PTCA drug balloon catheter in the treatment of coronary artery lesions in situ (ChiCTR) - P=N/A | N=370 | Completed | Sponsor: The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University

New trial

Recurrent coronary artery in-stent restenosis caused by metal allergy: a case report. (PubMed, Front Cardiovasc Med) - "The first ISR occurred after implantation of a nickel-rich Medtronic Endeavor Resolute stent (35% nickel, 35% cobalt, and 20% chromium)...The article discusses this special case and clinically relevant management options. This case highlights a scenario with refractory in-stent restenosis persisting despite various treatment strategies, including stents with different metal components, drug-coated balloons, and intensive drug therapy."

Journal • Allergy • Immunology

Short dual antiplatelet therapy after PCI with Resolute Onyx drug-eluting stents in high bleeding risk patients: One-year outcomes from a South Asian cohort. (PubMed, Am Heart J Plus) - "All patients received DAPT (aspirin 75 mg + ticagrelor 90 mg BID) for three months, followed by ticagrelor monotherapy for nine months. In this real-world HBR cohort treated with Resolute Onyx ZES, a strategy of 3-month DAPT followed by ticagrelor monotherapy was associated with low rates of ischemic events and the absence of major bleeding at one year. These findings suggest a favorable safety-efficacy balance for DAPT de-escalation in carefully selected patients; however, this requires confirmation in larger, prospective studies."

Journal • Acute Coronary Syndrome • Cardiovascular • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Thrombosis

IRIS-Onyx Cohort in the IRIS-DES Registry (clinicaltrials.gov) - P=N/A | N=4500 | Active, not recruiting | Sponsor: Seung-Jung Park | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Coronary Artery Disease

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) (clinicaltrials.gov) - P=N/A | N=300 | Active, not recruiting | Sponsor: Carelon Research | Trial completion date: Apr 2027 ➔ Feb 2028 | Trial primary completion date: Sep 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure

IRIS-Onyx Cohort in the IRIS-DES Registry (clinicaltrials.gov) - P=N/A | N=4500 | Recruiting | Sponsor: Seung-Jung Park | Trial completion date: Dec 2029 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

Clinical and Angiographic Outcomes of Cardiac Balloon-Mounted Stents for Symptomatic Intracranial Stenosis. (PubMed, Oper Neurosurg) - "The Resolute/Frontier stent demonstrated favorable safety and efficacy in this cohort, with low procedural complication rates and no recurrent strokes or intracranial hemorrhages at follow-up. These findings, along with previous evidence supporting drug-eluting stents, highlight the potential of Resolute/Frontier Onyx as a promising therapeutic option for symptomatic ICAD."

Journal • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Hypertension

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) (clinicaltrials.gov) - P=N/A | N=300 | Active, not recruiting | Sponsor: Carelon Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Heart Failure

RESOLUTE ONYX China RCT Study (clinicaltrials.gov) - P=N/A | N=550 | Active, not recruiting | Sponsor: Medtronic Vascular | Trial completion date: Sep 2025 ➔ Apr 2026

Trial completion date • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure

RESOLUTE ONYX China Single Arm Study (clinicaltrials.gov) - P=N/A | N=591 | Active, not recruiting | Sponsor: Medtronic Vascular | Trial completion date: Oct 2025 ➔ Apr 2026

Trial completion date • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure

ONYSOVER: Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Yonsei University | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

A randomized prospective study investigating the relationship between post-PCI wall shear stress and 12-month neointimal healing: The SHEAR-STENT study. (PubMed, Cardiovasc Revasc Med) - P=N/A | "The SHEAR-STENT study demonstrated no significant differences in WSS or NIT at 12 months between R-ZES and X-EES. A wide range of patient level correlation coefficients between WSS and NIT were observed, with some patients showing increased NIT was associated with low WSS and others associated with high WSS."

Journal • Diabetes • Dyslipidemia • Metabolic Disorders • Nephrology • Renal Disease

Single-center outcomes of Onyx drug-eluting balloon-mounted stents for neurovascular atherosclerotic disease. (PubMed, Interv Neuroradiol) - "Independent predictors of complications included posterior circulation stenting (OR 13.8, p = .005), smaller stent diameter (OR 0.17, p = .03), and higher stent number (OR 14.7, p < .0001).ConclusionOnyx DES demonstrated excellent navigability, high technical success, and favorable long-term outcomes in patients with neurovascular atherosclerotic lesions. Together with growing comparative evidence, these findings suggest newer-generation DES may overcome limitations of earlier stent systems and merit further prospective evaluation."

Journal • Atherosclerosis • Cardiovascular

Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-risk. (PubMed, Eur Heart J Open) - P=N/A | "After enrolment, HR patients were identified according to prespecified criteria, and per protocol compared with HR patients treated in two randomized all-comer trials with Resolute-type zotarolimus-eluting stents (ZES). The significant difference in TVMI was driven by periprocedural events, as a landmark analysis at 7 days found no between-stent differences. https://clinicaltrials.gov/study/NCT04475380."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction

TREATMENT OF HYPERTENSIVE EMERGENCY AND FLASH PULMONARY EDEMA WITH RENAL ARTERY STENTING: A REVIEW OF PICKERING SYNDROME (CHEST 2025) - "He was managed with oxygen therapy via face mask as well as intravenous nitroglycerin infusion...Renal angiography identified a 95% right renal artery stenosis and was successfully treated with angioplasty and deployment of a Resolute Onyx 4.0mm x 34mm stent... Our patient was treated with intravascular ultrasound-guided stent placement resulting in cardiopulmonary stabilization. The management in our case suggests that renal artery intervention should be considered in patients presenting with unilateral renal artery stenosis and cardiac destabilization such as flash pulmonary edema even in the setting of a functioning contralateral kidney."

Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • CNS Disorders • Depression • Heart Failure • Hypertension • Psychiatry • Respiratory Diseases

IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact (clinicaltrials.gov) - P=N/A | N=3100 | Active, not recruiting | Sponsor: Medstar Health Research Institute | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2027 ➔ Sep 2026

Enrollment closed • HEOR • Trial primary completion date • Atherosclerosis • Cardiovascular

Zotarolimus-eluting stent in complex lesions versus non-complex lesions from Japanese all-comers registry (ESC-WCC 2025) - "ZES showed decent clinical result in complex lesions and non-complex lesions from Japanese real-world data."

Cardiovascular • Myocardial Infarction

Characteristics and Success of Intentional Stent Fracture in Drug-Eluting Coronary Stents for Use in Congenital Heart Disease. (PubMed, Pediatr Cardiol) - "A total of 61 stents were tested: Resolute Onyx small (3.5-4.0 mm, n = 9, 15%), Resolute Onyx large (4.5-5.0 mm, n = 11, 18%), Synergy XD (3.5-4.0 mm, n = 13, 21%), Synergy Megatron (3.5-5.0 mm, n = 15, 25%), and Xience Skypoint (3.5-5.0 mm, n = 13, 21%). Dilation of DES platforms using a standardized serial dilation protocol results in a high rate of intentional fracture with minimal foreshortening in ex vivo bench testing. These results may aid congenital interventional cardiologists using DES for CHD in the selection of stents and optimal techniques for intentional fracture in vivo."

Journal • Cardiovascular • Heart Failure • Musculoskeletal Diseases

Assessing mortality rates and predictors of cardiac death in diabetic and non-diabetic patients after left main percutaneous coronary intervention with the Resolute zotarolimus-eluting stent in Bangladesh: a comprehensive analysis. (PubMed, AsiaIntervention) - "The use of the Resolute ZES was associated with comparable outcomes in diabetic and non-diabetic patients undergoing left main PCI. Age, renal function, and certain procedural techniques are key predictors of cardiac death, emphasising the need for individualised patient assessment in LMCA disease management."

Journal • Cardiovascular • Coronary Artery Disease • Metabolic Disorders

Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. (PubMed, Heart) - P4 | "The SUGAR trial demonstrates that AES and O-ZES provide comparable long-term efficacy in preventing TLF in patients with DM undergoing PCI. These findings support the use of either stent type and highlight the importance of further long-term studies to optimise outcomes."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Thrombosis